Replying to @parthaskar @ShivaniM_KC @kamleshkhunti @FionaQuigs @ObesitySociety @PNewlandJones @HannahBeba @drpatrickholmes @scelee1 @Rezaidi
Interestingly I did a debate on the same topic at the Midland Diabetes & Endocrine meeting last week where I spoke for the same motion…No surprises I lost debate 😢 Diabetologist do not do advocacy for obese patients Learn from type 1 advocates @ABCDiab @UK_ASO @DUK_research
Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea resulted in significant improvements of AHI scores nejm.org/doi/abs/10.1056/NEJ…
Congratulations @kamleshkhunti proud moment for @SouthAsianHF three of its members recognised @profkcp @KamranAbbasi congratulations Kiran and Kamran
GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data
thelancet.com/journals/lanps…
Our paper on the effects of behavioural sleep intervention on Obesity @AbdTahrani @samiul_m @Feaz2011 @Nirantharakumar @UHBDiabetes onlinelibrary.wiley.com/doi/…
Safety of glucose lowering therapy in first trimester of pregnancy. GLP -1 slight increase risk CV defect link.springer.com/article/10…
Replying to @kamleshkhunti @docanoopmisra
@kamleshkhunti What is your rank with over 5K high quality publications 😱
Replying to @DrAsifQasim @RubenThurairaj
This is what most short cases and PACES coaching is about familiarising doctors with cases that appear in exams. The GMC again demonstrates a biased @gmcuk to anything IMG. I am a bit surprised @bmj_latest report which could have been more balanced @KamranAbbasi
Replying to @kamleshkhunti @MiAirports
Same experience at Frankfurt nearly missed the flight 😢
Replying to @DrDerekConnolly
@DrDerekConnolly If the dose is decreased weight goes up but less than placebo. Important to set realistic targets and have patient on board to manage expectations
Prof. Wasim Hanif OBE retweeted
📢 SAHF Poster Competition: Deadline 2 October!
There’s still time to submit your poster for the SAHF Poster Competition. Showcase your work at the SAHF Annual Conference and share your research with colleagues and delegates.
Submit by 2 October 2026.
Novo CagriSema shows superior weight loss to Tirzepatide novonordisk.com/news-and-med…
Great message from @AlexZverev on winning US open. Giving hope to millions of people with type 1 diabetes in countries without access to latest treatments @DiabetesUK @BT1DUK @IntDiabetesFed @Jazzsethi95 instagram.com/reel/DdP456yCB…
Replying to @SamaraAfzal
Still one of the greats of the game. Always pleasing to watch a batter who can play a straight drive
SURMONT 1 DXA study with Tirzepatide , 75% weight loss is fat mass and 25% lean mass which is comparable to placebo dom-pubs.onlinelibrary.wiley…









